Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Desktop Genetics Form CRISPR Partnership

NEW YORK (GenomeWeb) – Twist Bioscience and Desktop Genetics today announced that they have formed a partnership to develop and offer integrated experiment design and DNA synthesis tools to facilitate gene-editing research. 

Under the terms of the deal, Desktop will collaborate with its customers to computationally design sgRNA libraries for CRISPR applications in any cell line. These libraries will then be synthesized by Twist and shipped directly to customers.

Additional terms of the arrangement were not disclosed.

"Through this integrated service, customers will be able to utilize Desktop Genetics' design capabilities for optimized gene editing experiments with concurrent access to unparalleled DNA synthesis through our 10,000-well silicon chip technology," Twist CEO Emily Leproust said in a statement.

"By working with Twist Bioscience, we will be able to extend our services to thousands of customers, providing them with rapid access to the high-quality, high-throughput synthetic DNA needed for their functional genomic screens and CRISPR experiments," Desktop CEO Riley Doyle added.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.